Neuro3d Initiates Phase I Trials with ND7001, a New Mechanism Antidepressant and Anxiolytic Compound

27-Jan-2005

Neuro3d announced the initiation of Phase I clinical trials with ND7001, a new type of antidepressant drug with anxiolytic activity. ND7001 acts on a new target that has never been associated with depression or anxiety. It is the first representative of a new generation of psycho-active compounds potentially devoid of several problems seen with existing treatments.

Initially, a double-blind, placebo-controlled, single, dose-escalation study will be conducted to investigate safety, tolerability and pharmacokinetics. Thereafter, a multiple-dose study will be conducted which will also include qEEG recordings to provide evidence of CNS effects and active dose range.

"ND7001 is the first drug of its kind to enter clinical development," noted Cesare Mondadori, CSO of Neuro3d. "The drug acts via a new mechanism and is well tolerated in preclinical studies. Our studies in animals show that ND7001 not only meets the criteria of an antidepressant but also of an anxiolytic compound."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances